Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia

International Journal of Drug Policy

Volumn 26, Issue 11, 2015, Pages 1081-1087

  Luhmann, Niklas ^a   Champagnat, Julie ^a   Golovin, Sergey ^b   Maistat, Ludmila ^c   Agustian, Edo ^d   Inaridze, Ina ^e   Myint, Wai Moe ^a   Butsashvili, Maia ^f   Bouscaillou, Julie ^a  

^a République Démocratique du Congo   (Myanmar)

^b International Treatment Preparedness Coalition in Eastern Europe and Central Asia   (Russian Federation)

^c The International HIV/AIDS Alliance in Ukraine   (Ukraine)

^d Persaudaraan Korban Napza Indonesia (PKNI) Indonesian Drug User Network   (Indonesia)

^e Médecins du Monde Georgia   (Georgia)

^f Health Research Union   (Georgia)

Author keywords

Disease burden; Hepatitis C; People who inject drugs; Treatment access

Indexed keywords

DASABUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR;

ARTICLE; ASIA; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; EUROPE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEPATITIS C; HUMAN; INDONESIA; INTRAVENOUS DRUG ABUSE; LOWEST INCOME GROUP; MIDDLE INCOME GROUP; MYANMAR; NONHUMAN; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RUSSIAN FEDERATION; SOCIAL STATUS; TREATMENT DURATION; COMPLICATION; DEVELOPING COUNTRY; EASTERN EUROPE; HEALTH CARE DELIVERY; META ANALYSIS; SUBSTANCE ABUSE;

ASIA; DEVELOPING COUNTRIES; EUROPE, EASTERN; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84942196182     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.07.016     Document Type: Article

References (43)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. International Journal of Drug Policy 2007, 18(5):352-358.
2. Akkarathamrongsin S., Praianantathavorn K., Hacharoen N., Theamboonlers A., Tangkijvanich P., Poovorawan Y. Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand. Intervirology 2011, 54:10-16. 10.1159/000318884.
3. Alavi M., Grebely J., Micallef M., Dunlop A.J., Balcomb A.C., Day C.A., et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clinical Infectious Diseases 2013, 57(Suppl. 2):S62-S69. 10.1093/cid/cit305.
4. Bemoni Public Union & SCAD Programme Estimating the prevalence of injection drug use in five cities of Georgia 2009, Retrieved from: http://bemonidrug.org.ge/wp-content/uploads/2014/07/Estimating-the-Prevalence-of-Injection-Drug-Use-in-Five-Cities-of-Georgia.pdf (20.11.14).
5. Bouscaillou J., Champagnat J., Luhmann N., Avril E., Inaridze I., Miollany V. Hepatitis C among people who inject drugs in Tbilisi Georgia: An urgent need for prevention and treatment. International Journal of Drug Policy 2014, 25(5):871-878.
6. Butsashvili M., Kamkamidze G., Kajaia M., Morse D.L., Triner W., Dehovitz J., et al. Occupational exposure to body fluids among health care workers in Georgia. Occupational Medicine (London) 2012, 62(8):620-626. 10.1093/occmed/kqs121.
7. Deans G.D., Raffa J.D., Lai C., Fischer B., Krajden M., Amin J., et al. Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. Canadian Medical Association Journal 2013, 1(2). E68-7E6. 10.9778/cmajo.20130002.
8. Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases 2005, 40(Suppl. 5):S313-S320.
9. Dumchev K.V., Soldyshev R., Qian H.Z., Zezyulin O.O., Chandler S.D., Slobodyanyuk P., et al. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: A cross-sectional survey. Harm Reduction Journal 2009, 6:23. 10.1186/1477-7517-6-23.
10. Global Fund to Fight AIDS TB and Malaria Global fund financing of hepatitis C treatment. GF/B32/DPO7 2014, Retrieved from: http://www.theglobalfund.org/Knowledge/Decisions/GF/B32/DP07/ (23.01.15).
11. Gower E., Estes C., Blach S., Razavi-Shearer K., Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 2014, 61(1S):S45-S57. 10.1016/j.jhep.2014.07.027.
12. Grebely J., Dore G.J. What is killing people with hepatitis C virus infection?. Seminars in Liver Disease 2011, 31(4):331-339. 10.1055/s-0031-1297922.
13. Grebely J., Tyndall M.W. Management of HCV and HIV infections among people who inject drugs. Current Opinion in HIV and AIDS 2011, 6(6):501-507. 10.1097/COH.0b013e32834bcb36.
14. Grebely J., Dore G.J. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104:62-72. 10.1016/j.antiviral.2014.01.002.
15. Hanafiah K.M., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57(4):1333-1342. 10.1002/hep.26141.
16. Heimer R., Eritsyan K., Barbour R., Levina O.S. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. BMC Infectious Diseases 2014, 14(Suppl. 6):S6-S12. 10.1186/1471-2334-14-S12.
17. Kamel Boulos M.N., Resch B., Crowley D.N., Breslin J.G., Sohn G., Burtner R., et al. Crowdsourcing, citizen sensing and sensor web technologies for public and environmental health surveillance and crisis management: Trends, OGC standards and application examples. International Journal of Health Geographics 2011, 10(December):67. 10.1186/1476-072x-10-67.
18. Kim A.E., Lieberman A.J., Dench D. Crowdsourcing data collection of the retail tobacco environment: Case study comparing data from crowdsourced workers to trained data collectors. Tobacco Control 2014, (February). 10.1136/tobaccocontrol-2013-051298.
19. Leiter A., Sablinski T., Diefenbach M., Foster M., Greenberg A., Holland J., et al. Use of crowdsourcing for cancer clinical trial development. Journal of the National Cancer Institute 2014, 106(September):10. pii:dju258. 10.1093/jnci/dju258.
20. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128. 10.1016/S0140-6736(12)61728-0.
21. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A. Reference Group to the UN on HIV and Injecting Drug Use Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 2007, 372(9651):1733-1745. 10.1016/S0140-6736(08)61311-2.
22. Maticic M., Videcnik Zorman J., Gregorcic S., Schatz E., Lazarus J.V. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infectious Diseases 2014, 14(Suppl. 6):S14. 10.1186/1471-2334-14-S6-S14.
23. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. Journal of Viral Hepatitis 2006, 13(1):34-41.
24. Ministry of Health of Indonesia 2012 size estimation of key affected populations (Report) 2014, Retrieved from: http://www.kebijakanaidsindonesia.net/jdownloads/Publikasi%20Publication/2012_size_estimation_of_key_affected_populations_kaps.pdf (16.04.15).
25. Ministry of Health Myanmar Myanmar national strategic plan on HIV and AIDS 2011-2015, Retrieved from: http://www.jhsph.edu/research/centers-and-institutes/center-for-public-health-and-human-rights/_pdf/NSP%20Full%20Book%20Final.pdf (23.11.14).
26. Momenghalibaf A. Open Society Foundations New York. Hepatitis C treatment: Price, profits, and barriers to access 2014, Retrieved from: http://www.opensocietyfoundations.org/sites/default/files/hepatitis-c-treatment-20130807.pdf (01.12.14).
27. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378(9791):571-583.
28. Prasetyo A.A., Dirgahayu P., Sari Y., Hudiyono H., Kageyama S. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia. The Journal of Infection in Developing Countries 2013, 7(June (6)):453-467. 10.3855/jidc.2965.
29. Solomon S.S., Mehta S.H., Srikrishnan A.K., Solomon S., McFall A.M., Laeyendecker O., et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: A cross-sectional study. The Lancet Infectious Diseases 2015, 15(January (1)):36-45. 10.1016/S1473-3099(14)71045-X.
30. State Service of Ukraine on HIV\AIDS and other Socially Dangerous Diseases, WHO Office in Ukraine, International HIV/AIDS Alliance in Ukraine & the UN Joint Programme on HIV/AIDS National HIV/AIDS estimates in Ukraine as of beginning of 2012 2012, Retrieved from: http://www.google.fr/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&cad=rja&uact=8&ved=0CCMQFjAA&url=http%3A%2F%2Fwww.unaids.org.ua%2Ffiles%2FNational_Estimates_on_HIVAIDS_in_Ukraine_Eng.doc&ei=7RGtVIz4H4WuU9qUhOgK&usg=AFQjCNGBft9YxrC1oZIpWCBPO_2zjT70AQ&bvm=bv.83134100,d.d24 (20.11.14).
31. Taylor L.E., Swan T., Matthews G.V. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clinical Infectious Diseases 2013, 57(Suppl. 2):S118-S124. 10.1093/cid/cit326.
32. Thomas D.L., Strathdee S.A., Vlahov D. Long-term prognosis of hepatitis C virus infection. Journal of the American Medical Association 2000, 284(20):2592.
33. Turner A.M., Kirchhoff K., Capurro D. Using crowdsourcing technology for testing multilingual public health promotion materials. Journal of Medical Internet Research 2012, 14(June (3)):e79. 10.2196/jmir.2063.
34. UNITAID World Hepatitis Day: Why UNITAID is investing in hepatitis C (press release) 2014, UNITAID, Geneva, Retrieved from: http://www.unitaid.eu/en/resources/press-centre/20-news/statements/1376-world-hepatitis-day-why-unitaid-is-investing-in-hepatitis-c (23.01.15).
35. United Nations, Department of Economic and Social Affairs, Population Division World population prospects. The 2012 revision 2013, Retrieved from: http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm (01.12.14).
36. UNODC World drug report 2014, Retrieved from: http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf (10.04.15).
37. Walsh N., Maher L. HIV and viral hepatitis C coinfection in people who inject drugs: Implications of new direct acting antivirals for hepatitis C virus treatment. Current Opinion in HIV and AIDS 2012, 7:339-344.
38. WHO Resolution A63/15: Viral hepatitis. 63rd World Health Assembly 2010, March, Retrieved from: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf (23.11.14).
39. WHO Viral hepatitis. WHA67.6. 67th World Health Assembly 2014, May, Retrieved from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf (23.11.14).
40. WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014, April, Retrieved from: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ (01.12.14).
41. WHO Hepatitis C. Fact sheet 164 2014, April, Retrieved from: http://www.who.int/mediacentre/factsheets/fs164/en/.
42. Wylie L., Hutchinson S., Liddell D., Rowan N. The successful implementation of Scotland's Hepatitis C Action Plan: What can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. BMC Infectious Diseases 2014, 14(Suppl. 6). 10.1186/1471-2334-14-S6-S7.
43. Zhou Y.H., Liu F.L., Yao Z.H., Duo L., Li H., Sun Y., et al. Comparison of HIV-, HBV-, HCV- and Co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border region. PLoS ONE 2011, 6(January (1)):e16349. 10.1371/journal.pone.0016349.